Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans

This study investigates preexisting and vaccine-induced vector immunity in 30 participants of a Phase-1 VSV-EBOV Ebola vaccine trial. No preexisting immunity was detected, however humoral and cell-mediated immunity against internal VSV proteins was observed in up to 36% of vaccines.

Download Full-text

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

The Journal of Infectious Diseases ◽

10.1093/infdis/jiaa586 ◽

2020 ◽

Cited By ~ 1

Author(s):

Neil Goldstein ◽

Viki Bockstal ◽

Stephan Bart ◽

Kerstin Luhn ◽

Cynthia Robinson ◽

...

Keyword(s):

Immune Responses ◽

Neutralizing Antibodies ◽

Ebola Virus ◽

Phase 1 ◽

Booster Vaccination ◽

Controlled Study ◽

Adenovirus Serotype ◽

Cellular Immune Responses ◽

High Doses ◽

Cellular Immune

Abstract Background This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360. Methods Healthy US adults (N = 164) randomized into 10 groups received saline placebo or standard or high doses of Ad26 or MVA in 2-dose regimens at 7-, 14-, 28-, or 56-day intervals; 8 groups received booster Ad26 or MVA vaccinations on day 360. Participants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, neutralizing antibodies and cellular immune responses to Ebola virus glycoprotein. Results All regimens were well tolerated with no serious vaccine-related adverse events. Heterologous (Ad26,MVA [dose 1, dose 2] or MVA,Ad26) and homologous (Ad26,Ad26) regimens induced humoral and cellular immune responses 21 days after dose 2; responses were higher after heterologous regimens. Booster vaccination elicited anamnestic responses in all participants. Conclusions Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardless of interval or dose level. Heterologous 2-dose Ad26,MVA regimens containing an Ebola virus insert induce strong, durable humoral and cellular immune responses. Immunological memory was rapidly recalled by booster vaccination, suggesting that Ad26 booster doses could be considered for individuals at risk of Ebola infection, who previously received the 2-dose regimen.

Download Full-text

Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01

Vaccine ◽

10.1016/j.vaccine.2008.11.087 ◽

2009 ◽

Vol 27 (6) ◽

pp. 893-903 ◽

Cited By ~ 29

Author(s):

Arun V. Iyer ◽

Bapi Pahar ◽

Marc J. Boudreaux ◽

Nobuko Wakamatsu ◽

Alma F. Roy ◽

...

Keyword(s):

West Nile Virus ◽

Immune Responses ◽

Vesicular Stomatitis Virus ◽

Virus Strain ◽

West Nile ◽

Lethal Challenge ◽

Cellular Immune Responses ◽

West Nile Virus Strain ◽

Vesicular Stomatitis ◽

Cellular Immune

Download Full-text

Prime-Boost Vaccination with Recombinant Mumps Virus and Recombinant Vesicular Stomatitis Virus Vectors Elicits an Enhanced Human Immunodeficiency Virus Type 1 Gag-Specific Cellular Immune Response in Rhesus Macaques

Journal of Virology ◽

10.1128/jvi.00550-09 ◽

2009 ◽

Vol 83 (19) ◽

pp. 9813-9823 ◽

Cited By ~ 10

Author(s):

R. Xu ◽

F. Nasar ◽

S. Megati ◽

A. Luckay ◽

M. Lee ◽

...

Keyword(s):

Immune Responses ◽

Vesicular Stomatitis Virus ◽

Rhesus Macaques ◽

Mumps Virus ◽

Cellular Immune Responses ◽

Immunodeficiency Virus ◽

Vesicular Stomatitis ◽

Cellular Immune ◽

Hiv 1

ABSTRACT Intramuscular inoculation of rhesus macaques with one or more doses of recombinant vesicular stomatitis virus (rVSV) expressing human immunodeficiency virus type 1 (HIV-1) Gag (rVSVgag) typically elicits peak cellular immune responses of 500 to 1,000 gamma interferon (IFN-γ) enzyme-linked immunospots (ELISPOTS)/106 peripheral blood lymphocytes (PBL). Here, we describe the generation of a novel recombinant mumps virus (rMuV) expressing HIV-1 Gag (rMuVgag) and measure the Gag-specific cellular immune responses detected in rhesus macaques following vaccination with a highly attenuated form of rVSV expressing HIV-1 Gag (rVSVN4CT1gag1) and rMuVgag in various prime-boost combinations. Notably, peak Gag-specific cellular immune responses of 3,000 to 3,500 ELISPOTS/106 PBL were detected in macaques that were primed with rMuVgag and boosted with rVSVN4CT1gag1. Lower peak cellular immune responses were detected in macaques that were primed with rVSVN4CT1gag1 and boosted with rMuVgag, although longer-term gag-specific responses appeared to remain higher in this group of macaques. These findings indicate that rMuVgag may significantly enhance Gag-specific cellular immune responses when administered with rVSVN4CT1gag1 in heterologous prime-boost regimens.

Download Full-text

A Comparison of the Humoral and Cellular Immune Responses at Different Immunological Sites after Split Influenza Virus Vaccination of Mice

Scandinavian Journal of Immunology ◽

10.1111/j.1365-3083.2006.01862.x ◽

2007 ◽

Vol 65 (1) ◽

pp. 14-21 ◽

Cited By ~ 15

Author(s):

S. Hauge ◽

A. S. Madhun ◽

R. J. Cox ◽

K. A. Brokstad ◽

L. R. Haaheim

Keyword(s):

Influenza Virus ◽

Immune Responses ◽

Virus Vaccination ◽

Cellular Immune Responses ◽

Cellular Immune

Download Full-text

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Clinical and Vaccine Immunology ◽

10.1128/cvi.00157-17 ◽

2017 ◽

Vol 24 (9) ◽

Cited By ~ 13

Author(s):

Judith Falloon ◽

H. Keipp Talbot ◽

Craig Curtis ◽

John Ervin ◽

Diane Krieger ◽

...

Keyword(s):

Respiratory Syncytial Virus ◽

Immune Responses ◽

Phase 1 ◽

Second Phase ◽

Double Blind Study ◽

Protein Vaccine ◽

Double Blind ◽

Cellular Immune Responses ◽

Syncytial Virus ◽

Cellular Immune

ABSTRACT This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A (GLA) in a squalene-based 2% stable emulsion (GLA-SE). In this randomized, double-blind study, 261 subjects aged ≥60 years received inactivated influenza vaccine (IIV), a vaccine containing 120 μg sF with escalating doses of GLA (1, 2.5, or 5 μg) in SE, or a vaccine containing 80 μg sF with 2.5 μg GLA in SE. Subjects receiving 120 μg sF with 2.5 or 5 μg GLA were also randomized to receive IIV or placebo. Immunity to RSV was assessed by detection of microneutralizing, anti-F immunoglobulin G, and palivizumab-competitive antibodies and F-specific gamma interferon enzyme-linked immunosorbent spot assay T-cell responses. Higher adjuvant doses increased injection site discomfort, but at the highest dose, the reactogenicity was similar to that of IIV. Significant humoral and cellular immune responses were observed. The 120 μg sF plus 5.0 μg GLA formulation resulted in the highest responses in all subjects and in older subjects. These results confirm previous observations of vaccine tolerability, safety, and immunogenicity and were used to select the 120 μg sF plus 5.0 μg GLA formulation for phase 2 evaluation. (This study has been registered at ClinicalTrials.gov under registration no. NCT02289820.)

Download Full-text

Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial

Clinical Immunology ◽

10.1016/j.clim.2008.01.012 ◽

2008 ◽

Vol 127 (2) ◽

pp. 188-197 ◽

Cited By ~ 23

Author(s):

Elisabetta Peduzzi ◽

Nicole Westerfeld ◽

Rinaldo Zurbriggen ◽

Gerd Pluschke ◽

Claudia A. Daubenberger

Keyword(s):

Immune Responses ◽

Phase I ◽

Synthetic Peptide ◽

Malaria Vaccine ◽

Vaccine Trial ◽

Cellular Immune Responses ◽

Cellular Immune

Download Full-text

ESAT-6 Subunit Vaccination againstMycobacterium tuberculosis

Infection and Immunity ◽

10.1128/iai.68.2.791-795.2000 ◽

2000 ◽

Vol 68 (2) ◽

pp. 791-795 ◽

Cited By ~ 236

Author(s):

Lise Brandt ◽

Martin Elhay ◽

Ida Rosenkrands ◽

Erik B. Lindblad ◽

Peter Andersen

Keyword(s):

Immune Responses ◽

Lipid A ◽

T Cell Response ◽

Cell Mediated Immunity ◽

Adjuvant Activity ◽

Humoral Immune ◽

Cellular Immune Responses ◽

Humoral Immune Responses ◽

Monophosphoryl Lipid A ◽

Cellular Immune

ABSTRACT The ESAT-6 antigen from Mycobacterium tuberculosis is a dominant target for cell-mediated immunity in the early phase of tuberculosis (TB) in TB patients as well as in various animal models. The purpose of our study was to evaluate the potential of ESAT-6 in an experimental TB vaccine. We started out using dimethyl dioctadecylammonium bromide (DDA), an adjuvant which has been demonstrated to be efficient for the induction of cellular immune responses and has been used successfully before as a delivery system for TB vaccines. Here we demonstrate that, whereas immune responses to both short-term-culture filtrate and Ag85B are efficiently induced with DDA, this adjuvant was inefficient for the induction of immune responses to ESAT-6. Therefore, we investigated the modulatory effect of monophosphoryl lipid A (MPL), an immunomodulator which in different combinations has demonstrated strong adjuvant activity for both cellular and humoral immune responses. We show in the present study that vaccination with ESAT-6 delivered in a combination of MPL and DDA elicited a strong ESAT-6-specific T-cell response and protective immunity comparable to that achieved withMycobacterium bovis BCG.

Download Full-text

Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria

Science ◽

10.1126/science.3281260 ◽

1988 ◽

Vol 240 (4850) ◽

pp. 336-338 ◽

Cited By ~ 168

Author(s):

JC Sadoff ◽

WR Ballou ◽

LS Baron ◽

WR Majarian ◽

RN Brey ◽

...

Keyword(s):

Immune Responses ◽

Salmonella Typhimurium ◽

Plasmodium Berghei ◽

Protein A ◽

Cell Mediated Immunity ◽

Specific Cell ◽

T Cell Epitopes ◽

Subunit Vaccines ◽

Cellular Immune Responses ◽

Cellular Immune

Immunization with radiation-attenuated malaria sporozoites induces potent cellular immune responses, but the target antigens are unknown and have not previously been elicited by subunit vaccines prepared from the circumsporozoite (CS) protein. A method is described here for inducing protective cell-mediated immunity to sporozoites by immunization with attenuated Salmonella typhimurium transformed with the Plasmodium berghei CS gene. These transformants constitutively express CS antigens and, when used to immunize mice orally, colonize the liver, induce antigen-specific cell-mediated immunity, and protect mice against sporozoite challenge in the absence of antisporozoite antibodies. These data indicate that the CS protein contains T cell epitopes capable of inducing protective cell-mediated immunity, and emphasize the importance of proper antigen presentation in generating this response. Analogous, orally administered vaccines against human malaria might be feasible.

Download Full-text

Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats

BMC Veterinary Research ◽

10.1186/s12917-020-02740-6 ◽

2021 ◽

Vol 17 (1) ◽

Author(s):

Xiaojuan Xue ◽

Zhaorong Yu ◽

Hongyan Jin ◽

Lin Liang ◽

Jiayang Li ◽

...

Keyword(s):

Immune Responses ◽

G Proteins ◽

Vesicular Stomatitis Virus ◽

Neutralizing Antibodies ◽

Recombinant Adenovirus ◽

Neutralizing Antibody ◽

Negative Control ◽

Antibody Titers ◽

Vesicular Stomatitis ◽

Cellular Immune

Abstract Background Vesicular stomatitis (VS) is an acute, highly contagious and economically important zoonotic disease caused by the vesicular stomatitis virus (VSV). There is a need for effective and safe stable recombinant vaccine for the control of the disease. The human type 5 replication-defective adenovirus expression vector is a good way to construct recombinant vaccines. Results Three recombinant adenoviruses (rAd) were successfully constructed that expressed the VSV Indiana serotype glycoprotein (VSV-IN-G), VSV New Jersey serotype glycoprotein (VSV-NJ-G), and the G fusion protein (both serotypes of G [VSV-IN-G-NJ-G]) with potentiality to induce protective immunity. G proteins were successfully expressed with good immunogenicity. The rAds could induce the production of VSV antibodies in mice, and VSV neutralizing antibodies in goats, respectively. The neutralizing antibody titers could reach 1:32 in mice and 1:64 in goats. The rAds induced strong lymphocyte proliferation in mice and goats, which was significantly higher compared to the negative control groups. Conclusions The three rAds constructed in the study expressed VSV-G proteins and induced both humoral and cellular immune responses in mice and goats. These results lay the foundation for further studies on the use of rAds in vaccines expressing VSV-G.

Download Full-text